logo

SCIELE PHA(NSDQ:SCRX)
Sciele Pharma, Inc., formerly known as First Horizon Pharmaceutical Corp., is a pharmaceutical company specializing in sales, marketing and the development of branded prescription products focused on Cardiovascular/Metabolic and Women''s Health. The Company''s Cardiovascular/Metabolic products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type two diabetes, and its Women''s Health products are designed improve the health and well-being of mothers and their babies. The Company''s success is based on placing the needs of patients first, improving health and quality of life and implementing its business platform an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and Teamwork.
# Employees: 900
Address: 5 Concourse Parkway Suite 1800,Atlanta,GA,USA
Phone: 770 442-9707
Fax: 770 442-9594
Website: www.sciele.com
Email: ir@sciele.com
Sector: Medical
Industry: MED-DRUGS
Executive Officers
Pierre Lapalme (Chmn.)
Patrick P. Fourteau (Presi.; C.E.O.; Dir.)
Darrell Borne (Exec. V.P.; C.F.O.; Sec.; Treas.)
Jon S. Saxe (Dir.)
Jerry N. Ellis (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 6/30/2008
Next Earnings Date(Expected): 11/4/2008
Mean EPS (Next Qtr): $0.69
Mean EPS (Year): $1.92
Mean Estimate(Long Term): $21.00
P/E Ratio(Based on EPS estimate): 16.140
Number of Estimates: 6
Shares Performance
Period SCRX Compare to S&P
YTD 51.39 % 101.19 %
4 Weeks 0.42 % 24.85 %
12 Weeks 56.36 % 92.87 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1556178
Shares Outstanding: 32M
Market Cap: $1.00B
52 Week High: $31.00
52 Week Low: $17.15
P/E Ratio: 18.110
PEG Ratio: 0.770
Split: On 9/25/2001 SCRX split by factor of 1.500
Earnings Performance
EPS Growth in Last Quarter: 31.43 %
EPS Growth in Last Year: 17.95 %
Sales Growth in Last Quarter: 2.79 %
Sales Growth in Last Quarter: 7.92 %
Financials
Qtr Book Value: $2.60
Cash Flow/Share: $12.99
Change in Payout Ratio: -0.010
Price/Sales: -0.010
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia